NVO novonordisk.com: שווי פעילות לרווח לפני ריבית, מסים ופחת

Novo Nordisk A/S (NVO) dominance in the weight loss and diabetes segment creates a powerful defensive barrier for profits. The EV/EBITDA value, accounting for total debt, has stabilized at 5.47 on the base chart of the GURU.Markets service, confirming the resilience of the valuation. Growth is driven by breakthrough GLP-1 developments in peptide engineering and a zero-environmental-footprint strategy for the recycling of medical devices.
Novo Nordisk - פילוחים אנליטיים ומדדי מפתח (NVO)

Investors use this ratio to determine the fair value of a company relative to its ability to generate cash flow. The metric compares the total enterprise value, including net debt, with operating profit before taxes, depreciation, and amortization. By analyzing the historical EV/EBITDA multiple of a business, one can identify points of asset undervaluation. For Novo Nordisk A/S (NVO), this metric reflects the efficiency of integrating new drug delivery platforms acquired through strategic M&A transactions.